GB0317227D0 - Treatment of male sexual dysfunction - Google Patents

Treatment of male sexual dysfunction

Info

Publication number
GB0317227D0
GB0317227D0 GBGB0317227.7A GB0317227A GB0317227D0 GB 0317227 D0 GB0317227 D0 GB 0317227D0 GB 0317227 A GB0317227 A GB 0317227A GB 0317227 D0 GB0317227 D0 GB 0317227D0
Authority
GB
United Kingdom
Prior art keywords
treatment
sexual dysfunction
male sexual
ejaculation
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0317227.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Pfizer Inc
Original Assignee
Pfizer Ltd Great Britain
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain, Pfizer Inc filed Critical Pfizer Ltd Great Britain
Priority to GBGB0317227.7A priority Critical patent/GB0317227D0/en
Publication of GB0317227D0 publication Critical patent/GB0317227D0/en
Priority to AP2005003376A priority patent/AP2005003376A0/xx
Priority to AT04709303T priority patent/ATE349449T1/de
Priority to SI200430160T priority patent/SI1597260T1/sl
Priority to BRPI0407676-1A priority patent/BRPI0407676A/pt
Priority to OA1200500229A priority patent/OA13029A/en
Priority to PT04709303T priority patent/PT1597260E/pt
Priority to MXPA05008923A priority patent/MXPA05008923A/es
Priority to DE602004003914T priority patent/DE602004003914T2/de
Priority to GEAP20048945A priority patent/GEP20074089B/en
Priority to EA200501136A priority patent/EA009460B1/ru
Priority to CA002516557A priority patent/CA2516557C/en
Priority to JP2006500323A priority patent/JP4033886B2/ja
Priority to AU2004213242A priority patent/AU2004213242B2/en
Priority to PL378747A priority patent/PL378747A1/pl
Priority to DK04709303T priority patent/DK1597260T3/da
Priority to KR1020057015408A priority patent/KR100750028B1/ko
Priority to EP04709303A priority patent/EP1597260B1/en
Priority to RSP-2005/0638A priority patent/RS20050638A/sr
Priority to ES04709303T priority patent/ES2277237T3/es
Priority to HR20050681A priority patent/HRP20050681A2/hr
Priority to CL200401702A priority patent/CL2004001702A1/es
Priority to CA002533177A priority patent/CA2533177A1/en
Priority to BRPI0412255-0A priority patent/BRPI0412255A/pt
Priority to AT04743961T priority patent/ATE380048T1/de
Priority to EP04743961A priority patent/EP1656183B1/en
Priority to PCT/IB2004/002300 priority patent/WO2005006899A1/en
Priority to JP2006520920A priority patent/JP2006528171A/ja
Priority to MXPA05014200A priority patent/MXPA05014200A/es
Priority to TW093121513A priority patent/TW200510424A/zh
Priority to US10/895,630 priority patent/US20050026810A1/en
Priority to UAA200508142A priority patent/UA79674C2/uk
Priority to ZA200505957A priority patent/ZA200505957B/en
Priority to IS7957A priority patent/IS2450B/is
Priority to EC2005005973A priority patent/ECSP055973A/es
Priority to MA28447A priority patent/MA27712A1/fr
Priority to TNP2005000200A priority patent/TNSN05200A1/fr
Priority to NO20054053A priority patent/NO20054053L/no
Priority to JP2006277701A priority patent/JP2007045838A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0317227.7A 2003-02-19 2003-07-23 Treatment of male sexual dysfunction Ceased GB0317227D0 (en)

Priority Applications (39)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction
EP04709303A EP1597260B1 (en) 2003-02-19 2004-02-09 Triazole compounds useful in therapy
RSP-2005/0638A RS20050638A (sr) 2003-02-19 2004-02-09 Triazolska jedinjenja korisna u terapiji
ES04709303T ES2277237T3 (es) 2003-02-19 2004-02-09 Compuestos de triazol utiles en terapia.
SI200430160T SI1597260T1 (sl) 2003-02-19 2004-02-09 Spojine triazola, uporabne pri terapiji
BRPI0407676-1A BRPI0407676A (pt) 2003-02-19 2004-02-09 compostos de triazol,uso e processos para fabricação do mesmo
OA1200500229A OA13029A (en) 2003-02-19 2004-02-09 Triazole compounds useful in therapy.
PT04709303T PT1597260E (pt) 2003-02-19 2004-02-09 Composto de triazole úteis em terapia
MXPA05008923A MXPA05008923A (es) 2003-02-19 2004-02-09 Compuestos de triazol utiles en terapia.
DE602004003914T DE602004003914T2 (de) 2003-02-19 2004-02-09 Für die therapie geeignete triazolverbindungen
GEAP20048945A GEP20074089B (en) 2003-02-19 2004-02-09 Triazole compounds useful in therapy
EA200501136A EA009460B1 (ru) 2003-02-19 2004-02-09 Триазольные соединения, полезные в терапии
CA002516557A CA2516557C (en) 2003-02-19 2004-02-09 Triazole compounds useful in therapy
JP2006500323A JP4033886B2 (ja) 2003-02-19 2004-02-09 治療に有用なトリアゾール化合物
AU2004213242A AU2004213242B2 (en) 2003-02-19 2004-02-09 Triazole compounds useful in therapy
PL378747A PL378747A1 (pl) 2003-02-19 2004-02-09 Związki triazolowe użyteczne w terapii
DK04709303T DK1597260T3 (da) 2003-02-19 2004-02-09 Triazol forbindelser, der er anvendelige i behandling
KR1020057015408A KR100750028B1 (ko) 2003-02-19 2004-02-09 치료에 유용한 트리아졸 화합물
AT04709303T ATE349449T1 (de) 2003-02-19 2004-02-09 Für die therapie geeignete triazolverbindungen
AP2005003376A AP2005003376A0 (en) 2003-02-19 2004-02-09 Triazole compounds useful in therapy.
HR20050681A HRP20050681A2 (en) 2003-02-19 2004-02-09 Triazole compounds useful in therapy
CL200401702A CL2004001702A1 (es) 2003-07-23 2004-07-06 Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida.
AT04743961T ATE380048T1 (de) 2003-07-23 2004-07-12 Behandlung der männlichen sexuellen dysfunktion
BRPI0412255-0A BRPI0412255A (pt) 2003-07-23 2004-07-12 tratamento da disfunção sexual masculina
MXPA05014200A MXPA05014200A (es) 2003-07-23 2004-07-12 Tratamiento de la disfuncion sexual masculina.
CA002533177A CA2533177A1 (en) 2003-07-23 2004-07-12 Treatment of male sexual dysfunction
EP04743961A EP1656183B1 (en) 2003-07-23 2004-07-12 Treatment of male sexual dysfunction
PCT/IB2004/002300 WO2005006899A1 (en) 2003-07-23 2004-07-12 Treatment of male sexual dysfunction
JP2006520920A JP2006528171A (ja) 2003-07-23 2004-07-12 男性機能障害の治療
TW093121513A TW200510424A (en) 2003-07-23 2004-07-19 Treatment of male sexual dysfunction
US10/895,630 US20050026810A1 (en) 2003-07-23 2004-07-20 Treatment of male sexual dysfunction
UAA200508142A UA79674C2 (en) 2003-07-23 2004-09-02 Triazol compounds suitable for use in therapeutics
ZA200505957A ZA200505957B (en) 2003-07-23 2005-07-25 Triazole compounds useful in therapy
IS7957A IS2450B (is) 2003-02-19 2005-07-25 Tríasól efnasambönd sem eru gagnleg við meðferð
EC2005005973A ECSP055973A (es) 2003-02-19 2005-08-19 Compuestos de triazol utiles en terapia
MA28447A MA27712A1 (fr) 2003-02-19 2005-08-19 Triazoles utiles en therapeutique
TNP2005000200A TNSN05200A1 (fr) 2003-02-19 2005-08-19 Triazoles utiles en therapeutique
NO20054053A NO20054053L (no) 2003-02-19 2005-08-31 Triazolforbindelser anvendbare i terapi.
JP2006277701A JP2007045838A (ja) 2003-02-19 2006-10-11 治療に有用なトリアゾール化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
GB0317227D0 true GB0317227D0 (en) 2003-08-27

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0317227.7A Ceased GB0317227D0 (en) 2003-02-19 2003-07-23 Treatment of male sexual dysfunction

Country Status (12)

Country Link
EP (1) EP1656183B1 (https=)
JP (1) JP2006528171A (https=)
AT (1) ATE380048T1 (https=)
BR (1) BRPI0412255A (https=)
CA (1) CA2533177A1 (https=)
CL (1) CL2004001702A1 (https=)
GB (1) GB0317227D0 (https=)
MX (1) MXPA05014200A (https=)
TW (1) TW200510424A (https=)
UA (1) UA79674C2 (https=)
WO (1) WO2005006899A1 (https=)
ZA (1) ZA200505957B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
WO2006100557A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment
CN117414361A (zh) * 2023-09-28 2024-01-19 华中农业大学 一种化合物在预防和治疗革兰氏阴性菌病方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
WO2005006899A1 (en) 2005-01-27
CL2004001702A1 (es) 2005-05-13
ZA200505957B (en) 2006-11-29
TW200510424A (en) 2005-03-16
BRPI0412255A (pt) 2006-09-19
JP2006528171A (ja) 2006-12-14
EP1656183A1 (en) 2006-05-17
UA79674C2 (en) 2007-07-10
MXPA05014200A (es) 2006-07-03
CA2533177A1 (en) 2005-01-27
ATE380048T1 (de) 2007-12-15
EP1656183B1 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
MXPA03007513A (es) Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
SG122820A1 (en) Process for the distillation of a mixture of isomeric diisocyanatodiphenylmethanes
TW200407305A (en) Novel compounds
TNSN07195A1 (en) Potentiators of glutamate receptors
IL181473A0 (en) Humanized anti-beta 7 antagonists and uses therefor
EA200901099A1 (ru) Соединения и способы модулирования сопряженных с g-белком рецепторов
NO20050471L (no) Fremgangsmate for telomerisasjon av ikke-sykliske olefiner
CL2004000545A1 (es) Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
TW200420543A (en) Treatment of female sexual dysfunction
TW200621244A (en) Modulators of muscarinic receptors
WO2004056763A3 (en) Novel glucagon antagonists
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
MXPA05011630A (es) Metodo para aumentar la hidrofobicidad de la superficie de las tazas de inodoro.
IL164016A0 (en) Azetidine derivatives as ccr-3 receptor antagonists
GB0317227D0 (en) Treatment of male sexual dysfunction
WO2002100350A3 (en) Dopamine receptor ligands and therapeutic methods based thereon
PT1673354E (pt) Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
WO2007014263A3 (en) Octahydroisoquinoline compounds as opioid receptor modulators
TW200606145A (en) Asymmetric hydrogenation process
MXPA05012572A (es) Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central.
MX2007006382A (es) Moduladores de receptores muscarinicos.
WO2004103289A3 (en) Driverse thyroid hormone receptor antagonists and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)